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Abstract
Introduction Previous studies in mouse models and pilot
epidemiology studies have demonstrated that inherited
polymorphisms are associated with inherited risk of tumor
progression and poor outcome in human breast cancer. To
extend these studies and gain better understanding of the
function of inherited polymorphism in breast cancer
progression, a validation prognosis study was performed in a
large independent breast cancer patient population.
Methods The study population consisted of 1863 Dutch
patients with operable primary breast cancer from Rotterdam,
The Netherlands. Genomic DNA was genotyped for the
missense Pro436Leu RRP1B single nucleotide polymorphism
(SNP) rs9306160 and the intronic SIPA1 SNP rs2448490 by
SNP-specific PCR.
Results A significant association of variants in RRP1B with
metastasis-free survival was observed (P = 0.012), validating
the role of RRP1B with inherited metastatic susceptibility.
Stratification of patients revealed that association with patients'
survival was found to be specifically restricted to estrogen
receptor positive, lymph node-negative (ER+/LN-) patients (P =
0.011). The specific association with metastasis-free survival
only in ER+/LN- patients was replicated for SIPA1, a second
metastasis susceptibility gene known to physically interact with
RRP1B (P = 0.006). Combining the genotypes of these two
genes resulted in the significant ability to discriminate patients
with poor metastasis-free survival (HR: 0.40, 95% CI: 0.24 to
0.68, P = 0.001).
Conclusions These results validate SIPA1 and RRP1B as
metastasis susceptibility genes and suggest that genotyping
assays may be a useful supplement to other clinical and
molecular indicators of prognosis. The results also suggest that
lymphatic and hematogeneous metastases are genetically
distinct that may involve different mechanisms. If true, these
results suggest that metastatic disease, like primary breast
cancer, may be multiple diseases and that stratification of late
stage patients may therefore be required to fully understand
breast cancer progression and metastasis.
Introduction
Cancer mortality can be attributed mostly to metastatic dis-
ease, with an estimated 90% of deaths associated with solid
tumors resulting from the pathophysiological impact of sec-
ondary disease. Despite many advances in both basic science
and applied clinical research over recent years, advanced dis-
seminated disease remains an incurable condition. Further
investigations into the myriad of factors associated with meta-
static disease are therefore warranted to identify critical
molecular nodes and targets in this complex process that will
enable development and deployment of new or improved clin-
ical tools for combating the effects of advanced disseminated
disease.
One of these factors for breast cancer is inherited metastatic
susceptibility. Recently, using a mouse model system, it was
demonstrated that germline polymorphisms have significant
effects on the ability of a transgene-induced mouse mammary
tumor to metastasize [1-3]. Subsequently, using small pilot
clinical cohorts, significant associations with markers of poor
outcome were observed, consistent with the presence of
metastasis susceptibility in the human populations [4,5].
CI: confidence interval; DFS: disease-free survival; ER: ostrogen receptor; HER: human epidermal growth factor receptor; HR: hazard ratio; LN: lymph 
node; MFS: metastasis-free survival; OS: overall survival; PCR: polymerase chain reaction; PR: progesterone receptor; SNP: single nucleotide poly-
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Descriptive epidemiology studies further support this hypoth-
esis, demonstrating familial clustering of outcome in a variety
of different cancer types [6-11].
The current study builds on and extends the previous studies
of the first two identified metastasis efficiency modifier genes,
SIPA1 [3] and RRP1B [4]. Using a much larger cohort, signif-
icant associations between polymorphisms in these genes
and advanced disease were identified replicating earlier stud-
ies. Unexpectedly, however, these associations were
restricted to subgroups of patients after stratification by the
estrogen receptor (ER) and lymph node (LN) status. The
results suggest that at least for inherited metastatic suscepti-
bility in breast cancer that these subpopulations could be bio-
logically distinct with different pathways leading to the
metastatic disease.
Materials and methods
Patient population
The protocol to study biological markers associated with dis-
ease outcome was approved by the medical ethics committee
of the Erasmus Medical Center Rotterdam, The Netherlands
(MEC 02.953). This retrospective study used coded primary
tumor tissue, in accordance with the Code of Conduct of the
Federation of Medical Scientific Societies in the Netherlands
[12] and, as much as possible, was reported in line with the
REMARK guidelines [13]. The single nucleotide polymor-
phisms (SNPs) were determined in 1863 tumor tissues. ER
levels were missing for nine patients and progesterone recep-
tor (PR) levels for 104 patients. Data for one of the two SNPs
were not available for 25 tumors. The final study includes
breast tumor tissue specimens of 1725 female Dutch patients
with primary operable breast cancer (990 patients underwent
a mastectomy, 735 patients underwent breast-conserving
lumpectomy) who entered the clinic in Rotterdam between
1979 and 2002 with ER and PR levels known as well as both
SNPs rs2448490 and rs9306160. Radiotherapy was given to
1162 patients as part of primary treatment. Adjuvant therapy
was not performed as part of the primary treatment for LN-
patients. Of the LN+ patients, 24% (187 of 766) were
received systemic adjuvant therapy. The median follow up of
alive patients was 90 months (range, 4 to 231 months). The
clinical questions addressed in the present study include the
associations of the various SNP frequencies with patient and
tumor characteristics, and prognosis in primary breast cancer.
Tumor ER and PR levels were determined in cytosolic extracts
by routine ligand binding assay or by enzyme immunoassay
[14]. The cut point to classify primary breast tumors as ER
and/or PR positive was 10 fmol/mg cytosolic protein. None of
the patients had received neo-adjuvant therapy. Details on
patient and tumor characteristics are presented in Table 1.
DNA isolation and whole genome amplification
Genomic DNA was isolated from two to ten 30 μm cryostat
sections (5 to 20 mg) with the NucleoSpin®Tissue kit (Mach-
erey-Nagel; Bioké, Leiden, The Netherlands) according to the
protocol provided by the manufacturer. The quantity and qual-
ity of the isolated DNA was established by ultraviolet spectros-
copy, by examination of the product size after agarose gel
electrophoresis, and by the ability of the sample to be linearly
amplified by real-time PCR in a serial dilution with a set of prim-
ers located in an intron of the hydroxymethylbilane synthase on
chromosome 11 and thymidine kinase on chromosome 17.
Samples not showing a DNA band of at least 20 kb or at 5 to
25 ng DNA not amplifiable by both real-time PCR assays were
excluded. Prior to SNP genotyping, 10 ng aliquots of genomic
DNA were amplified with the GenomiPhi V2 DNA amplification
kit (GE Healthcare, Piscataway, NJ, USA) according to the
protocol provided by the manufacturer, typically yielding 4 μg
amplifiable genomic DNA with the 20 kb band still visible on
gel.
SNP selection and genotyping
SIPA1 and RRP1B polymorphisms were characterized using
allele-specific PCR. PCR primers were designed using Vector
NTI 9.0 software (Invitrogen, Carlsbad, CA, USA) according to
parameters described elsewhere [15] or purchased from
Applied Biosystems (Foster City, CA, USA). Each probe was
labeled with a reporter dye (either VIC® (a proprietary fluores-
cent dye produced by Applied Biosystems) or FAM (5-(&6)-
carboxyfluorescein)) specific for wildtype and variant alleles of
each SNP.
The RRP1B SNP rs9306160 was previously described [4].
Briefly, it encodes a Pro436Leu missense mutation in the
RRP1B protein, and tags an approximately 200 kb haplotype
block encompassing both RRP1B and the adjacent HSF2BP
gene. The primers and probes for the RRP1B were as follows,
5'-3': forward, TGGACGTGGCCTCTGCAC; reverse, CAC-
CACCTGCAGCCTGAAA; Vic labeled, AGGGCTTTCG-
GCCCAG; FAM labeled AGGGCTTTCAGCCCAGAG. The
SIPA1 SNP rs2448490 was genotyped using the ABI assay
C__15797548_10.
Reaction mixtures consisted of 300 nM of each oligonucle-
otide primer, 100 nM fluorogenic probes 8 ng template DNA,
and 2× TaqMan Universal PCR Master Mix (Applied Biosys-
tems, Foster City, CA, USA) in a total volume of 10 μl. The
amplification reactions were performed in a MJ Research DNA
Engine thermocycler (Bio-Rad, Hercules, CA, USA) with two
initial hold steps (50°C for 2 minutes, followed by 95°C for 10
minutes) and 40 cycles of a two-step PCR (92°C for 15 sec-
onds, 60°C for 1 minute). The fluorescence intensity of each
sample was measured post-PCR in an ABI Prism 7900 HT
sequence detection system (Applied Biosystems, Foster City,
CA, USA), and genotypes were determined by the fluores-
cence ratio of the nucleotide-specific fluorogenic probes. TheAvailable online http://breast-cancer-research.com/content/11/5/R75
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Table 1
Genotype distributions by patient and tumor characteristics
SIPA1 rs2448490 RRP1B rs9306160
GG AG AA CC CT TT
Characteristic Patients n (%) n (%) n (%) n (%) n (%) n (%)
Total 18631 748 (40) 807 (43) 293 (16) 616 (33) 904 (49) 333 (18)
Age (years)
≤40 239 98 (41) 98 (41) 43 (18) 82 (34) 123 (51) 34 (14)
41-55 736 301 (41) 323 (44) 103 (14) 235 (32) 359 (49) 139 (19)
56-70 597 228 (39) 265 (45) 98 (17) 193 (33) 285 (48) 114 (19)
>70 291 121 (42) 121 (42) 49 (17) 106 (37) 137 (47) 46 (16)
P = 0.661 P = 0.481
Menopausal status
Premenopausal 823 334 (41) 364 (45) 117 (14) 268 (33) 419 (51) 135 (16)
Postmenopausal 1040 414 (40) 443 (43) 176 (17) 348 (34) 485 (47) 198 (19)
P = 0.288 P = 0.165
Lymph nodes involved
0 1095 441 (41) 459 (42) 183 (17) 358 (33) 535 (49) 192 (18)
1-3 350 134 (38) 165 (47) 50 (14) 107 (31) 180 (51) 63 (18)
>3 418 173 (42) 183 (44) 60 (14) 151 (36) 189 (45) 78 (19)
P = 0.438 P = 0.459
Tumor size
pT1 686 280 (41) 289 (43) 109 (16) 209 (31) 340 (50) 131 (19)
pT2 977 390 (40) 435 (45) 148 (15) 333 (34) 461 (47) 180 (18)
pT3/4 200 78 (40) 83 (42) 36 (18) 74 (37) 103 (52) 22 (11)
P = 0.789 P = 0.049
Grade
Poor 1007 403 (40) 437 (44) 162 (16) 326 (33) 508 (51) 168 (17)
Good/moderate 282 113 (41) 120 (43) 44 (16) 101 (36) 122 (44) 56 (20)
Unknown 574 232 (41) 250 (44) 87 (15) 189 (33) 274 (48) 109 (19)
P = 0.994 P = 0.280
ER status
Positive 1367 529 (39) 606 (45) 219 (16) 445 (33) 666 (49) 249 (18)
Negative 487 217 (45) 194 (40) 74 (15) 169 (35) 233 (48) 82 (17)
P = 0.087 P = 0.625
PR status
Positive 1149 442 (39) 521 (46) 174 (15) 369 (32) 563 (49) 212 (19)
Negative 601 267 (45) 232 (39) 99 (17) 207 (35) 290 (49) 99 (17)
P = 0.018 P = 0.459
1Due to missing values the numbers do not always add up to 1863.
2All P values derived from Pearson's chi-squared statistics.
xER = oestrogen receptor; PR = progesterone receptor.Breast Cancer Research    Vol 11 No 5    Hsieh et al.
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genotyping success rate for rs2448490 was 99.2% (2491 of
2511 samples, controls and duplicates). The success rate for
rs9306160 was 99.3%. The concordance rate for rs2448490
was 98.3% (404 of 411 duplicates) and 98.1% (404 of 411)
for rs9306160.
Statistical analysis
Pearson's chi-squared statistic was used to study the relation
of the variant SNP alleles with patient and tumor characteris-
tics. The hazard ratios (HRs) for SNPs and traditional prognos-
tic factors were determined with Cox proportional hazards
models for both univariate (disease-free survival (DFS), metas-
tasis-free survival (MFS), and overall survival (OS)) and multi-
variate regression analyses (with backward elimination) in
1725 patients. The assumption of proportional hazards was
checked using Schoenfeld residuals. We stratified for ER
because the assumption of proportionality was violated for ER.
MFS was considered the major endpoint for the prognostic
study. The endpoint for DFS was defined as any recurrence of
the disease (958 events) including secondary breast cancer in
the contralateral breast. Metastasis was defined as any distant
recurrence (772 events) not including secondary breast can-
cer or local or regional recurrences. For OS, death from any
cause was considered an event (n = 684). The HRs are repre-
sented with their 95% confidence intervals (CI).
Survival curves were generated using the Kaplan-Meier
method, a log-rank test was used to test for differences
between the survival curves or when appropriate the log-rank
test for trend. Computations were performed with the STATA
statistical package, release 10.0 (STATA Corp, College Sta-
tion, TX, USA). All P values were two-sided, and P < 0.05 was
considered statistically significant.
Results
SNP selection
Previous studies with SIPA1 revealed some potential associ-
ations with LN metastasis [5], but no significant associations
with distant MFS or patient survival [5,16]. Recent examination
of the HapMap database [17], however, indicated that the pre-
vious SNPs did not tag all of the haplotype blocks for this
gene. As a result, the tagged SIPA1 SNP rs2448490 was
selected to provide more comprehensive SIPA1 coverage in
addition to the previously metastasis associated RRP1B
rs9306160 for genotyping in this cohort.
Analysis of SNP frequencies and tumor characteristics
The SNPs were genotyped in 1863 breast cancer cases. The
frequencies of the variant alleles were 37.5% for rs2448490
A and 42.5% for rs9306160 T. rs9306160 was found to be in
Hardy-Weinberg equilibrium, while rs2448490 was not in this
population. No significant or strong relations of any of the SNP
genotypes with patient's age or menopausal status, tumor
size, LN status or hormone receptor status were observed
(Table 1). Tumors from homozygote carriers of the RRP1B
rs9306160 T allele tended to be smaller tumors in this cohort
(P = 0.049). SIPA1 SNP rs2448490 was found to be associ-
ated with the tumor steroid hormone receptor status (ER, P =
0.087; PR, P = 0.018; Table 1).
SNP associations with prognosis in primary breast 
cancer
SNP allele frequencies were subsequently examined for their
associations with prognosis. Survival analyses were con-
ducted for 1,725 patients with both SNPs determined and ER
and PR status known. Since SIPA1 and RRP1B had been
previously associated with risk of metastatic progression,
metastasis-free survival (MFS) was considered the primary
endpoint for this study. Disease-free survival (DFS) and overall
survival (OS) were included to examine the associations of
these genes with disease relapse and overall outcome.
Consistent with our previous observations [4], patients carry-
ing T allele (CT or TT) of RRP1B SNP rs9306160 showed a
favorable prognosis for MFS and the same trends for DFS and
OS, when compared with the wildtype CC. Based on these
results, the CT and TT patients were grouped together assum-
ing either an additive or dominant effect of the T allele and the
univariate analysis repeated. Under this model significant
associations of the T allele with better outcome were observed
for MFS and OS (DFS (HR: 0.88, 95% CI: 0.77 to 1.01, P =
0.063); MFS (HR: 0.80, 95% CI: 0.69 to 0.92, P = 0.002);
OS (HR: 0.85, 95% CI: 0.73 to 1.00, P = 0.046)). Multivariate
analysis was then performed to determine whether the T allele
was an independent prognostic factor when compared with
standard clinical factors. Only the association with MFS was
significant in multivariate analysis (Table 2) while the associa-
tions of the T allele with DFS and OS were partly confounded
in the multivariate analysis and not statistically significant (data
not shown). Adjuvant chemotherapy did not affect the esti-
mated coefficients of the RRP1B SNP rs9306160 genotype.
As the proportional hazards assumption was violated by ER,
we stratified the patients. LN- patients were not treated with
systemic adjuvant therapy while LN+ patients did receive sys-
temic treatment. This enabled us to evaluate associations in
four subgroups, LN-/ER+ with good prognosis and LN-/ER-,
LN+/ER+ and LN+/ER- with an expected poor prognosis.
Surprisingly, the association of the variant T allele in RRP1B
rs9306160 with a favorable prognosis was significant only for
the subgroup of LN-/ER+ patients (Figure 1a), but not in the
other patient subgroups (LN+/ER+ (Figure 1b), LN-/ER-,
LN+/ER- (not shown)). This association was statistically signif-
icant for DFS and MFS in multivariate analysis (DFS (HR: 0.75,
95% CI: 0.60 to 0.94, P = 0.013), MFS (HR: 0.70, 95% CI:
0.54 to 0.91, P = 0.009) and OS (HR: 0.78, 95% CI: 0.59 to
1.03, P = 0.082)).
The variant A allele of SIPA1 rs2448490 was also found to be
associated with better outcome after stratification by ER andAvailable online http://breast-cancer-research.com/content/11/5/R75
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LN status. Patients homozygous for the A allele had a favora-
ble MFS (Figure 1c) and OS (HR: 0.57, 95%CI: 0.38 to 0.86,
P = 0.007 HR: 0.64, 95%CI: 0.43 to 0.97, P = 0.036). A sim-
ilar trend, although not statistically significant, was found for
DFS. The associations were significant in the multivariate anal-
ysis for DFS (HR: 0.73, 95% CI: 0.54 to 0.99, P = 0.042),
MFS (HR: 0.56, 95% CI: 0.37 to 0.84, P = 0.005) and OS
(HR: 0.59, 95% CI: 0.39 to 0.89, P = 0.012).
SIPA1 SNP rs2448490/RRP1B SNP rs9306160 
combination
Previous studies demonstrated that the SIPA1 and RRP1B
gene products physically interact [4]. As the SIPA1  SNP
rs2448490 and RRP1B SNP rs9306160 were both associ-
ated with a favorable prognosis in LN-/ER+ patients, we
explored the possibility that they were independent predictors
of MFS and that the combination of both SNP genotypes
might show increased prognostic power. Indeed, SIPA1 SNP
rs2448490 and RRP1B  SNP rs9306160 remained inde-
pendent predictors of MFS if both SNPs were included in the
final multivariate model (Table 3). Kaplan-Meier analysis for
MFS as a function of the combined genotypes in the LN-/ER+
patients showed that the combination of the homozygous AA
variant allele of SIPA1 SNP rs2448490 and the T variant allele
(CT+TT) of RRP1B SNP rs9306160 was the best prognosti-
cator (Figure 1d). The risk for developing distant metastasis
was about 2.5-fold lower for patients with this genotype com-
bination compared with carriers of the GG and GA/CC geno-
type combination (HR: 0.40, 95% CI: 0.24 to 0.68, P  =
0.001).
Discussion
Significant advances have been made in the understanding of
breast cancer in the past decade. It is now understood that
there are at least four molecular subtypes: luminal A, luminal B,
basal and human epidermal growth receptor (HER)2-positive
tumors [18]. Furthermore, a variety of studies have demon-
strated that gene expression profiles can discriminate
between patients of differing outcome. As a result, a number
of different commercial assays are currently available [19] to
aid patients and clinicians in their decisions for therapeutic
intervention, two of which are currently in prospective clinical
trials [20,21]. Despite the importance of these findings, the
origins of the gene expression signatures are unclear. Based
on the prevailing model, it was presumed gene expression sig-
natures would be the result of an accumulation of somatic
mutations during the evolution of the tumor. However, the abil-
ity to discriminate patient outcome based on bulk tumor
expression data was considered inconsistent with that hypoth-
esis, because only a small fraction of the tumor would be pre-
dicted to express the appropriate signature, as predicted by
the progression model [22]. These observations have led to a
renewed discussion into the molecular mechanisms of breast
cancer metastasis [23,24].
Studies in our laboratory have suggested that one of the pre-
viously unknown factors contributing to breast cancer metas-
tasis is genetic background. Using an animal model system,
we demonstrated that the genetic background had a signifi-
cant impact on its ability to form pulmonary metastases [2].
Subsequently, systems genetics approaches have identified a
number of polymorphic metastasis efficiency genes
[3,4,25,26]. These results therefore suggest that the prognos-
tic gene expression signatures currently in clinical trials may be
in part due to inherited polymorphism rather than somatic
mutation, and may be a surrogate for inherited metastasis sus-
ceptibility segregating in the human population. This interpre-
tation is strengthened by the recent demonstration that
prognostic gene expression signatures pre-exist between nor-
mal tissues of animals of high- or low-metastatic genotypes
Table 2
Final model for multivariate analysis of MFS in all patients1
Characteristic HR (95% CI) P
Age (years)
41-55 vs. ≤ 40 0.88 (0.71-1.10) 0.265
56-70 vs. ≤ 40 0.70 (0.5-0.98) 0.036
>70 vs. ≤ 40 0.62 (0.43-0.90) 0.013
Menopausal status
Post vs. premenopausal 1.30 (1.01-1.67) 0.045
Lymph nodes involved
1-3 vs. 0 1.80 (1.49-2.18) < 0.001
>3 vs. 0 2.73 (2.29-3.25) < 0.001
Tumor size
pT2 vs. pT1 1.56 (1.32-1.86) < 0.001
pT3/4 vs. pT1 1.84 (1.44-2.36) < 0.001
Grade
Good/moderate vs. poor 0.56 (0.43-0.72) < 0.001
Unknown vs. poor 0.91 (0.77-1.06) 0.221
ER
Positive vs. negative 0.79 (0.65-0.96) 0.016
PR
Positive vs. negative 0.82 (0.69-0.98) 0.032
RRP1B rs9306160
CT+TT vs. CC 0.83 (0.71-0.96) 0.012
SIPA1 rs2448490
GG+GA vs. AA 0.85 (0.69-1.05) 0.129
11725 patients
CI = confidence interval; ER = estrogen receptor; HR = hazard ratio; 
MFS = metastasis-free survival; PR = progesterone receptor.Breast Cancer Research    Vol 11 No 5    Hsieh et al.
Page 6 of 9
(page number not for citation purposes)
[27]. Taken together, these data support the hypothesis that
genotype-based assays may be a valuable complement or
supplement to clinical and gene expression-based prognostic
tools.
This study therefore builds on the preliminary epidemiology
studies of two of our previously described metastasis effi-
ciency genes, SIPA1 [5] and RRP1B, a chromatin associated
protein of unknown function [4,28]. Initial investigations of
SIPA1 did not reveal associations with MFS [5,16]. However,
recent analysis of HapMap database [17] indicated that the
SNPs investigated in these previous studies did not com-
pletely haplotype-tag this locus. Therefore an additional SNP
was investigated in this study to improve coverage. In contrast,
evidence for an association with a polymorphism in RRP1B
and MFS had been previously observed in two small pilot
cohorts [4]. This study therefore sought to replicate these
results in a larger cohort, as well as to investigate whether
there was a genetic, in addition to the physical, interaction
between RRP1B and SIPA1 [4].
The results of these studies suggest a number of important
points. First, as predicted by the mouse genetic and pilot epi-
demiology studies, genetic background is likely to be an
important factor for human breast cancer progression
because significant associations were observed for both
genes. Although the results are consistent with these associ-
ations resulting from inherited predisposition an important
caveat of this study is that it is also formally possible that these
results stem from copy number variation in the tumor DNA
used, which is the only material available from this unique
cohort. We believe, however, that this is unlikely for the follow-
ing reasons. First, the results are consistent with the previous
studies which were performed in constitutional DNA from nor-
mal lymphocytes. For RRP1B at least, this is unlikely to be a
false-positive result because the same association has now
been observed in three independent patient populations. Sec-
Figure 1
Kaplan-Meier analysis of MFS for SIPA1 and RRP1B SNPs on stratified patient populations Kaplan-Meier analysis of MFS for SIPA1 and RRP1B SNPs on stratified patient populations. (a) RRP1B rs9306160 in node-negative, estrogen 
receptor (ER)-positive patients; (b) RRP1B rs9306160 in node-positive, ER-positive patients; (c) SIPA1 rs2448490 in node-negative, ER-positive 
patients; (d) Combination of SIPA1 rs2448490 and RRP1B rs9306160 in node-negative, ER-positive patients. LN = lymph node; MFS = metasta-
sis-free survival.Available online http://breast-cancer-research.com/content/11/5/R75
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ond, the allele frequencies of the SNPs does not vary between
tumor types and subgroups, as might be expected if there was
a preferential copy number change in a subset of tumors. Thus
although at this time we can not formally rule out a contribution
of somatic evolution we favor the hypothesis that these effects
are likely due to inherited factors. Future replication in an inde-
pendent cohort based on constitutional DNA will be resolve
this possibility.
The second major point, as suggested by the physical interac-
tion of the gene products, is that the combination of the SIPA1
and RRP1B SNPs is an independent predictor of MFS when
compared with standard clinical parameters, capable of dis-
criminating high-risk, intermediate-risk and low-risk individuals.
This combination SNP assay may therefore provide a valuable
addition to current methods. This SNP assay would have a
number of advantages over current gene expression based
assays. As it is based on constitutional DNA it can be per-
formed from routinely collected peripheral blood, rather than
tumor tissue, which require more invasive procedures. In addi-
tion, because DNA is more stable than RNA, there are fewer
constraints on collection, handling and processing proce-
dures. Furthermore, genotyping methods are relatively inex-
pensive, robust and rapid, and thus would likely be significantly
less expensive than expression array based methods.
In addition to the potential clinical benefit, this study has impor-
tant implications for our understanding of the mechanisms of
metastatic progression. The fact that these polymorphisms are
predictive of MFS in LN-, ER+, but not other subgroups sug-
gest that at least for inherited metastatic susceptibility, there
must be at least two pathways for metastatic progression. The
lack of association in the LN+ samples indicates that these
individuals are not simply diagnosed at a later time along a lin-
ear progression pathway. Instead, it suggests that those
tumors that spread through the vasculature and those that
seed the lymphatics likely use distinct molecular pathways dur-
ing dissemination. This interpretation is consistent with previ-
ous observations in the literature. Analysis of breast cancer
subtypes as defined by gene expression profiles [18] demon-
strated preferential sites of relapse [29], suggesting different
mechanisms of colonization. In addition, women with triple-
negative breast cancers (ER-, PR-, HER2-) are less likely to
experience a local recurrence before developing a distant
recurrence [30]. Similarly, BRCA1 carriers have been shown
to be less likely to have positive axillary LNs at diagnosis than
non-hereditary breast cancers [31]. To our knowledge, how-
ever, this is the first example of the ability of common allelic var-
iants to discriminate patient outcome in specific clinical tumor
types.
Although these results are consistent with constitutional pre-
disposition to metastatic disease and suggest that the inher-
ited susceptibilities for tumors that disseminate to the LNs is
different than those that metastasize directly distant organs,
the mechanisms used are currently unknown. It is possible that
the allelic variants of these two genes might significantly alter
the likelihood of tumors activating different pathways; for
example, angiogenesis versus lymphangiogenesis, which
would be expected to help direct tumor cells away from or
toward sentinel LNs. At present, however, neither of these
genes have been directly implicated in these pathways. SIPA1
is a RAPGAP signaling molecule [32] and RRP1B is a chro-
matin associated protein of unknown function [28]. Both mol-
ecules have been previously implicated in the expression of
extracellular matrix genes, which in and of themselves have
been associated with metastatic progression. As these vari-
ants are present in constitutional DNA the effect of the differ-
ent alleles on metastatic disease could be due to modulation
of tumor cells, the microenvironments the cells encounter or a
combination of both. At present it is not clear which of these
possibilities is most applicable. Because of these multiple pos-
sibilities and the complexity of each component, the exact bio-
logical mechanism by which these molecules operate is
therefore likely to be complex and require significant additional
efforts to unravel the exact mechanistic details.
Conclusions
In summary, this study replicates the previous association of
RRP1B with MFS and establishes a previously unknown asso-
ciation with SIPA1. Combination of these SNPs enables effec-
Table 3
Final model for multivariate analysis of MFS in ER+ lymph 
node-negative patients1
Characteristic HR (95% CI) P
Age (years)
41-55 vs. ≤ 40 0.72 (0.49-1.06) 0.101
56-70 vs. ≤ 40 0.43 (0.28-0.65) < 0.001
>70 vs. ≤ 40 0.44 (0.28-0.70) 0.001
Tumor size
pT2 vs. pT1 1.41 (1.07-1.84) 0.013
pT3/4 vs. pT1 1.82 (0.95-3.51) 0.073
Grade
Good/moderate vs. Poor 0.58 (0.38-0.87) 0.009
Unknown vs. Poor 1.05 (0.79-1.39) 0.729
SIPA1 rs2448490
AA vs. AG+GG 0.56 (0.38-0.85) 0.006
RRP1B rs9306160
CT+TT vs. CC 0. 71 (0.54-0.92) 0.011
1761 patients
CI = confidence interval; ER = estrogen receptor; HR = hazard ratio; 
MFS = metastasis-free survival.Breast Cancer Research    Vol 11 No 5    Hsieh et al.
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tive discrimination of patients into high-risk, intermediate-risk
and low-risk categories for MFS, independent of standard clin-
ical parameters. Furthermore, the association of genetic sus-
ceptibility for MFS only in specific clinical subgroups indicates
that multiple molecular mechanisms for metastatic progres-
sion are likely to be involved in breast cancer progression. Fur-
ther investigations into the utility of these polymorphisms,
including validation in additional retrospective cohorts, analy-
sis in prospective clinical trials, and analysis of the effect of the
variants on the molecular biology of the tumor and host are
clearly warranted to provide further insights into the role of
inherited polymorphism in breast cancer dissemination and
metastasis.
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